Delineate

Executive Summary

Delineate is a YC W25-backed pre-seed AI startup building specialized agents that extract and structure data from biopharma literature, patents, and graphical figures to accelerate clinical trial design — a real pain point in a market growing at 40%+ CAGR. The founding team has exceptional founder-market fit (MIT Biological Engineering PhD, Pfizer, AstraZeneca), and early engagement with two top-tier pharma companies is a genuine signal for a company this young. The claims largely hold up, though funding figures vary across sources ($500K vs. $3.2M seed) and customer names are undisclosed. The single biggest risk is a combination of two-customer revenue concentration and Big Pharma's credible ability to replicate this capability in-house — if either anchor customer walks, the company is in trouble.